| Nov 14 |
GH Research GAAP EPS of -$0.23 beats by $0.02
|
| Nov 14 |
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 10 |
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
|
| Sep 9 |
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
|
| Sep 9 |
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
|
| Sep 3 |
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Sep 3 |
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
|
| Jun 2 |
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
|
| May 31 |
Psychedelic stocks mixed as FDA comments on MDMA therapy (update)
|
